stockrow
Saturday 7 November 2026
Export ZBIO’s income statement to Excel — free account
Zenas BioPharma, Inc.
ZBIO Healthcare Biotechnology
Zenas BioPharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, up 100.0% from fiscal 2024.
- EPS
- −35.3%
- Free cash flow
- −41.0%
Quarter to September 2026, against a year earlier
28.26
2.33
+8.99%
Follow ZBIO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (265.11%) | (199.04%) | (137.11%) | (136.22%) |
+8 more TTM periods Free account |
|
| (108.66%) | (97.39%) | (78.63%) | (100.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(100.44%) | (82.38%) | (63.55%) | (130.91%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(3.67) | (3.58) | (3.78) | (3.85) | |
Free Cash Flow |
(242.83) | (225.97) | (210.48) | (172.35) | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.02) | |
| Other line items | |||||
Cash ROIC |
(30.44%) | (17.67%) | (15.00%) | (25.96%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
334.57% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
106.60% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
60.10% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.45 | 0.47 | 0.50 | 0.46 | |
Depreciation/Fixed assets |
1.26 | 1.35 | 1.39 | 1.65 | |
Capex/Depreciation |
(0.12) | (0.06) | (0.05) | (0.32) | |
Revenue per Share |
1.07 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.67) | (3.58) | (3.78) | (3.85) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026